1.50Open0.90Pre Close3 Volume59 Open Interest210.00Strike Price450.00Turnover46.25%IV13.94%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.50Extrinsic Value100Contract SizeAmericanOptions Type-0.1024Delta0.0061Gamma161.51Leverage Ratio-0.1018Theta-0.0162Rho-16.54Eff Leverage0.1128Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet